FDA Approves ZTALMY for CDKL5 Deficiency Disorder
source: pixabay.com

FDA Approves ZTALMY for CDKL5 Deficiency Disorder

Until recently, patients with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) did not have an FDA-approved treatment option. This all changed when the regulatory agency granted approval to ZTALMY, also…

Continue Reading FDA Approves ZTALMY for CDKL5 Deficiency Disorder
Medical Professionals Discuss Guidelines for Psoriatic Arthritis
Aymanjed / Pixabay

Medical Professionals Discuss Guidelines for Psoriatic Arthritis

Recently, two medical professionals were interviewed where they discussed their recommendations for the guidelines pertaining to managing psoriatic arthritis. Psoriatic Arthritis Psoriatic arthritis is a type of inflammatory arthritis that…

Continue Reading Medical Professionals Discuss Guidelines for Psoriatic Arthritis
HCU Network America Partners With RARE X to Create a Patient Registry
source: pixabay.com

HCU Network America Partners With RARE X to Create a Patient Registry

Patient Worthy partner HCU Network America and RARE X, a rare disease patient data service organization, have recently partnered in order to create a registry of patients living with homocystinuria,…

Continue Reading HCU Network America Partners With RARE X to Create a Patient Registry
InformedDNA, Foundation Fighting Blindness Partnership Will Screen Patients for Usher Syndrome, RP Clinical Trials
source: pixabay.com

InformedDNA, Foundation Fighting Blindness Partnership Will Screen Patients for Usher Syndrome, RP Clinical Trials

ProQR Therapeutics is working to develop unique therapeutic solutions for genetic eye diseases. Currently, the company is evaluating its therapeutic candidate ultevursen within the Phase 2/3 Sirius and Celeste clinical trials; you can read…

Continue Reading InformedDNA, Foundation Fighting Blindness Partnership Will Screen Patients for Usher Syndrome, RP Clinical Trials
First Patient Dosed in WU-CART-007 Trial for Acute Lymphoblastic Leukemia
https://unsplash.com/photos/tV-RX0beDp8

First Patient Dosed in WU-CART-007 Trial for Acute Lymphoblastic Leukemia

Each year, an estimated 11,000 people across the globe are diagnosed with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL). However, there is only one…

Continue Reading First Patient Dosed in WU-CART-007 Trial for Acute Lymphoblastic Leukemia